In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

At TCT, A New Vision of the Device Industry

Executive Summary

The biggest news at this year's TCT meeting was, as anticipated, Boston Scientific's release of its latest TAXUS drug-eluting stent trial results, which showed slightly better binary restenosis rates than Johnson & Johnson's SIRIUS trial. The TAXUS results appeared to trigger a 4.5% drop in J&J's share price, surprising given that the TAXUS results weren't a dramatic improvement, but indicative of how much the companies involved with DES have at stake.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV002192

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel